Ayana is a pharmaceutical company focused in the field of Liposomal Therapeutics, for the treatment of Cancer.

  • The company leverages the benefits of the anticancer drug, Doxil – an FDA approved liposomal nanodrug.
  • Cancer Indications:
    Ovarian Cancer, Metastatic Breast Cancer, Multiple Myeloma and AIDS-related Kaposi’s Sarcoma.
  • Based on Prof. Barenholz’ invention, Doxil® was first developed and marketed by J&J, reaching peak sales of $900M.
Read More

Co-founded by one of Doxil’s co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions.

Milestones:
  • Completed clinical studies, demonstrating in vitro equivalence and clinical bioequivalence to the marketed Doxil.
  • The drug is currently under FDA review for premarketing approval, expected 2020.
  • Shown commercial manufacturing capability in a
    GMP facility, in over 20 batches.
  • GMP manufacturing facility passed FDA inspection

The Production process

error: Content is protected !!